Related references
Note: Only part of the references are listed.Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure
Max S. Schreuer et al.
MELANOMA RESEARCH (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
Simon Chang-Hao Tsao et al.
SCIENTIFIC REPORTS (2015)
Quantitative Cell-Free Circulating BRAF(V600E) Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors
Miguel F. Sanmamed et al.
CLINICAL CHEMISTRY (2015)
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors
Allison Ackerman et al.
CANCER (2014)
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
Paolo Antonio Ascierto et al.
CANCER INVESTIGATION (2014)
Double-stranded DNA in exosomes: a novel biomarker in cancer detection
Caitlin Williams et al.
CELL RESEARCH (2014)
Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2014)
Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib
L. Peuvrel et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Circulating BRAFV600E in the Diagnosis and Follow-Up of Differentiated Papillary Thyroid Carcinoma
C. Pupilli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma
Sail Abusaif et al.
MELANOMA RESEARCH (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies
Stephanie Du Four et al.
EUROPEAN JOURNAL OF CANCER (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy
Kim A. Margolin et al.
SEMINARS IN ONCOLOGY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
The origin of circulating free DNA
Maniesh van der Vaart et al.
CLINICAL CHEMISTRY (2007)
Circulation DNA: Biological implications for cancer metastasis and immunology
Z Chen et al.
MEDICAL HYPOTHESES (2005)
About the possible origin and mechanism of circulating DNA - Apoptosis and active DNA release
M Stroun et al.
CLINICA CHIMICA ACTA (2001)
Share Paper
